| Verf.angabe: | Michela Carlotta Massi, Francesca Gasperoni, Francesca Ieva, Anna Maria Paganoni, Paolo Zunino, Andrea Manzoni, Nicola Rares Franco, Liv Veldeman, Piet Ost, Valérie Fonteyne, Christopher J. Talbot, Tim Rattay, Adam Webb, Paul R. Symonds, Kerstie Johnson, Maarten Lambrecht, Karin Haustermans, Gert De Meerleer, Dirk de Ruysscher, Ben Vanneste, Evert Van Limbergen, Ananya Choudhury, Rebecca M. Elliott, Elena Sperk, Carsten Herskind, Marlon R. Veldwijk, Barbara Avuzzi, Tommaso Giandini, Riccardo Valdagni, Alessandro Cicchetti, David Azria, Marie-Pierre Farcy Jacquet, Barry S. Rosenstein, Richard G. Stock, Kayla Collado, Ana Vega, Miguel Elías Aguado-Barrera, Patricia Calvo, Alison M. Dunning, Laura Fachal, Sarah L. Kerns, Debbie Payne, Jenny Chang-Claude, Petra Seibold, Catharine M. L. West, Tiziana Rancati and on behalf of the REQUITE Consortium |
|---|
| Abstract: | Background REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QUalITy of lifE in cancer survivors) is an international prospective cohort study. The purpose of this project was to analyse a cohort of patients recruited into REQUITE using a deep learning algorithm to identify patient-specific features associated with the development of toxicity, and test the approach by attempting to validate previously published genetic risk factors. Methods The study involved REQUITE prostate cancer patients treated with external beam radiotherapy who had complete 2-year follow-up. We used five separate late toxicity endpoints: ≥grade 1 late rectal bleeding, ≥grade 2 urinary frequency, ≥grade 1 haematuria, ≥ grade 2 nocturia, ≥ grade 1 decreased urinary stream. Forty-three single nucleotide polymorphisms (SNPs) already reported in the literature to be associated with the toxicity endpoints were included in the analysis. No SNP had been studied before in the REQUITE cohort. A Deep Sparse AutoEncoder (DSAE) was trained to recognize features (SNPs) identifying patients with no toxicity and tested on a different independent mixed population including patients without and with toxicity. Results 1401 patients were included, and toxicity rates were: rectal bleeding 11.7%, urinary frequency 4%, haematuria 5.5%, nocturia 7.8%, decreased urinary stream 17.1%. 24 of the 43 SNPs that were associated with the toxicity endpoints were validated as identifying patients with toxicity. Twenty of the 24 SNPs were associated with the same toxicity endpoint as reported in the literature: 9 SNPs for urinary symptoms and 11 SNPs for overall toxicity. The other 4 SNPs were associated with a different endpoint. Conclusion Deep learning algorithms can validate SNPs associated with toxicity after radiotherapy for prostate cancer. The method should be studied further to identify polygenic SNP risk signatures for radiotherapy toxicity. The signatures could then be included in integrated normal tissue complication probability models and tested for their ability to personalize radiotherapy treatment planning. |
|---|
Online-Ressource
